A Multicenter, Randomized, Double-Blind, PlaceboControlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata
|Effective start/end date||8/6/18 → 2/28/26|
- ELI LILLY AND COMPANY
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.